COVID-19 antibody self-test ready for mass production in June

Diagnostic technologies developer Mologic has joined forces with BioSure, self-testing specialists, to produce a COVID-19 antibody self-test.

By combining Mologic’s COVID-19 lateral flow test with BioSure’s design, the companies have created a self-test for COVID-19 that can be used without any training being required. The design has been proven to be easy to use, requires only a fraction of a drop of blood and gives the user their own result in 10 minutes. Since launching the first CE marked HIV self-test in 2015, BioSure have become world-leading experts in self-testing.

Mark Davis, CEO, Mologic: “Mologic is thrilled to be partnering with BioSure on this COVID-19 self-test, which will enable people to quickly and safely test for antibodies to the virus in their own home. The team and our independent validation partners have worked tirelessly to develop and optimise this quality rapid diagnostic in record time and this partnership brings it one step closer getting it on the market. To all those that have contributed to this project and supported us thus far, I offer my sincere gratitude.”

The BioSure COVID-19 Antibody Self-Test will be ready for mass production at the beginning of June. It will be available to the UK and global markets and will also be available to be directly purchased by end-consumers. 

Since March, alongside Liverpool School of Tropical Medicine (LSTM) and St George’s, University of London, leading laboratories across the world have partnered with Mologic to rapidly iterate, improve, and validate the Company’s COVID-19 diagnostic prototypes and independently assess performance. 

Brigette Bard, CEO of BioSure: “We are incredibly proud to announce our partnership with Mologic, the world-leading scientific researchers. Our companies are very aligned in their dynamic thinking and the way we both have a strong passion to find solutions to problems. Their expertise and creativity mean that together we have an outstanding test, that everyone, everywhere, will be able to test on their own terms. I cannot thank them enough for their phenomenal approach and extraordinary hard work and I would also like to thank the general public for their unwavering support. Our companies have already developed life-saving diagnostics across our individual product portfolios, including HIV and Ebola, and jointly we can now continue to accelerate our impact by putting the test into the end users’ hands, who will get their own result while they wait.”